REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide
Open Access
- 7 November 2025
- journal article
- Published by Elsevier in Kidney International
- Vol. 109 (1) , 6-16
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (UL1TR002319)
- National Institutes of Health (UM1AI109568)
- National Institutes of Health (OT2HL161847)
- National Institutes of Health (OT2OD032581)
- National Institutes of Health (U01DK100846)
- National Institutes of Health (U54DK083912)
- National Institutes of Health (U2CDK114886)
- National Institutes of Health (R01MD014712)
- Novo Nordisk
- Doris Duke Charitable Foundation
- Juvenile Diabetes Research Foundation Canada (3-SRA-2022-1243-M-B)
- Juvenile Diabetes Research Foundation Canada (3-SRA-2023-1373-M-B)
- Bayer
This publication has 26 references indexed in Scilit:
- Spatial transcriptomics defines injury specific microenvironments and cellular interactions in kidney regeneration and diseaseNature Communications, 2024
- Histopathologic Analysis of Human Kidney Spatial Transcriptomics DataThe American Journal of Pathology, 2024
- Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products–induced inflammationKidney International, 2023
- Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosisKidney International, 2022
- Bias and Precision in Magnetic Resonance Imaging‐Based Estimates of Renal Blood Flow: Assessment by TriangulationJournal of Magnetic Resonance Imaging, 2021
- The impact of chronic kidney disease on global healthNature Reviews Nephrology, 2020
- Consensus-based technical recommendations for clinical translation of renal T1 and T2 mapping MRIMagnetic Resonance Materials in Physics, Biology and Medicine, 2019
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trialThe Lancet Diabetes & Endocrinology, 2018
- Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney diseaseKidney International, 2018
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetesNature Reviews Nephrology, 2017